Literature DB >> 25874488

MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer.

Tian Yang1, Asmitananda Thakur, Tianjun Chen, Li Yang, Gao Lei, Yiqian Liang, Shuo Zhang, Hui Ren, Mingwei Chen.   

Abstract

MicroRNAs (miRNAs) play a critical role in cancer development and progression. Aberrant expression of miR-15a has recently been reported in several cancers, but its role in non-small cell lung cancer (NSCLC) still remains obscure. We investigated the effects of miR-15a on proliferation, apoptosis, and metastasis in A549 cells. Eighteen paired NSCLC and adjacent non-tumor lung tissues were surgically removed and immediately snap frozen until total RNA was extracted and confirmed by two independent pathologists. The targets of miR-15a were predicted by bioinformatics tools. RNA isolation and quantitative real-time PCR (qRT-PCR), Western blot analysis, cell proliferation assay, cell cycle analysis, cell apoptosis assay, and migration and invasion assays were done. The wild type (WT) or mutant type (MT) 3'-untranslated region (UTR) vectors were co-transfected with miR-15a or negative control into A549 cells, and after 24 h of transfection, luciferase activity was measured using the Dual-Glo luciferase assay kit. Statistical analysis was performed using SPSS 13.0 software (SPSS, Chicago, IL, USA). P values of less than 0.05 were considered statistically significant. miR-15a was significantly downregulated in NSCLC than in adjacent non-cancerous tissues. miR-15a overexpression remarkably inhibited cell viability, invasion, and migration and promoted the apoptosis of NSCLC cells. Additionally, inhibition of miR-15a expression had the opposite effects on tumor progression, while cell cycle remained unaltered. Furthermore, we identified that BCL2L2 was a target of miR-15a and negatively regulated by miR-15a at the translational level. miR-15a acts as a tumor suppressor in NSCLC by directly targeting BCL2L2 and may serve as a potential diagnostic biomarker and therapeutic target for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25874488     DOI: 10.1007/s13277-015-3075-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

1.  p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer.

Authors:  Lei Shi; Rene Jackstadt; Helge Siemens; Huihui Li; Thomas Kirchner; Heiko Hermeking
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

2.  MicroRNA-361-5p facilitates cervical cancer progression through mediation of epithelial-to-mesenchymal transition.

Authors:  Xiaomei Wu; Xiaowei Xi; Qin Yan; Zhenbo Zhang; Bin Cai; Wen Lu; Xiaoping Wan
Journal:  Med Oncol       Date:  2013-10-26       Impact factor: 3.064

3.  Mir-33 regulates cell proliferation and cell cycle progression.

Authors:  Daniel Cirera-Salinas; Montse Pauta; Ryan M Allen; Alessandro G Salerno; Cristina M Ramírez; Aranzazu Chamorro-Jorganes; Amarylis C Wanschel; Miguel A Lasuncion; Manuel Morales-Ruiz; Yajaira Suarez; Ángel Baldan; Enric Esplugues; Carlos Fernández-Hernando
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

4.  Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation.

Authors:  Hye Won Lee; Seung-Sook Lee; Sun Joo Lee; Hong-Duck Um
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

5.  MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA.

Authors:  Juan Qu; Liang Zhao; Pengzhi Zhang; Juan Wang; Ning Xu; Wenjuan Mi; Xingwang Jiang; Changming Zhang; Juan Qu
Journal:  J Cell Physiol       Date:  2015-03       Impact factor: 6.384

6.  BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line.

Authors:  Tsutomu Kawasaki; Sana Yokoi; Hitoshi Tsuda; Hiroyuki Izumi; Ken-Ichi Kozaki; Shinsuke Aida; Yuichi Ozeki; Yasuyuki Yoshizawa; Issei Imoto; Johji Inazawa
Journal:  Cancer Sci       Date:  2007-04-24       Impact factor: 6.716

7.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.

Authors:  Nora Bandi; Erik Vassella
Journal:  Mol Cancer       Date:  2011-05-16       Impact factor: 27.401

8.  MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.

Authors:  Y Xu; F Zhao; Z Wang; Y Song; Y Luo; X Zhang; L Jiang; Z Sun; Z Miao; H Xu
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

9.  Lung cancer biomarkers: State of the art.

Authors:  Sangeetha Subramaniam; Ram Krishna Thakur; Vinod Kumar Yadav; Ranjan Nanda; Shantanu Chowdhury; Anurag Agrawal
Journal:  J Carcinog       Date:  2013-02-28

10.  miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes.

Authors:  Pei-Shi Hung; Chung-Ji Liu; Chung-Shan Chou; Shou-Yen Kao; Cheng-Chieh Yang; Kuo-Wei Chang; Ting-Hui Chiu; Shu-Chun Lin
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more
  27 in total

1.  BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.

Authors:  Sarah T Diepstraten; Catherine Chang; Lin Tai; Jia-Nan Gong; Ping Lan; Alexander C Dowell; Graham S Taylor; Andreas Strasser; Gemma L Kelly
Journal:  Blood Adv       Date:  2020-01-28

2.  MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene.

Authors:  Christopher Alderman; Ayoub Sehlaoui; Zhaoyang Xiao; Yixin Yang
Journal:  Tumour Biol       Date:  2016-08-04

3.  BCL-W has a fundamental role in B cell survival and lymphomagenesis.

Authors:  Clare M Adams; Annette S Kim; Ramkrishna Mitra; John K Choi; Jerald Z Gong; Christine M Eischen
Journal:  J Clin Invest       Date:  2017-01-17       Impact factor: 14.808

4.  MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.

Authors:  Yun Liu; Xu Hu; Daokui Xia; Songlin Zhang
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

5.  miR-197 is downregulated in cervical carcinogenesis and suppresses cell proliferation and invasion through targeting forkhead box M1.

Authors:  Qiyan Hu; Ke Du; Xiaogang Mao; Siqing Ning
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

6.  MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R.

Authors:  Guannan Wu; Jiayun Liu; Zhenfeng Wu; Xiaoyu Wu; Xuequan Yao
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

7.  MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells.

Authors:  Shuai Li; Yulian Ma; Xinfang Hou; Ying Liu; Ke Li; Shuning Xu; Jufeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas.

Authors:  M Braoudaki; G I Lambrou; K Giannikou; S A Papadodima; A Lykoudi; K Stefanaki; G Sfakianos; A Kolialexi; F Tzortzatou-Stathopoulou; M Tzetis; S Kitsiou-Tzeli; E Kanavakis
Journal:  Tumour Biol       Date:  2016-01-26

9.  MicroRNA-337 regulates the PI3K/AKT and Wnt/β-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2.

Authors:  Hongzhang Cui; Ruijin Song; Ju Wu; Wei Wang; Xi Chen; Jiajun Yin
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

10.  Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients.

Authors:  Yahui Zhang; Yanpeng Zhao; Shengjie Sun; Zhefeng Liu; Yixin Zhang; Shunchang Jiao
Journal:  Tumour Biol       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.